Immunomedics to Present First Clinical Results With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immunomedics to Present First Clinical Results With Anti-HLA-DR Antibody for Treatment of Hematologic Malignancies at the 2015 Annual Meeting of the American Society of Hematology

MORRIS PLAINS, N.J., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Immunomedics, Inc. , (Nasdaq: IMMU ) today announced that it will present at the 57 th American Society of Hematology Annual Meeting, scheduled for December 5 – 8, 2015 in Orlando, FL, initial results on IMMU-114, the Company proprietary anti-HLA-DR antibody, which is in a Phase 1, first-in-man, clinical trial for patients with hematological cancers. The results will show excellent safety for the convenient subcutaneous administration, with first evidence of disease control in almost half of the patients. Details of the presentation are listed below:

Sunday, December 6, 2015

  • Subcutaneous Injections of IMMU-114 (Anti-HLA-DR IgG4 Monoclonal Antibody): Initial Results of a Phase I First-in-Man Study in Hematologic Malignancies (Stephens, et al.)

Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Poster II

Publication Number: 2740

Time and Location: 6:00 p.m. – 8:00 p.m., Hall A (Orange County Convention Center)

About Immunomedics

Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Immunomedics' advanced proprietary technologies allow the Company to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Using these technologies, Immunomedics has built a pipeline of nine clinical-stage product candidates. Immunomedics' most advanced candidate is 90 Y-clivatuzumab tetraxetan. The radiolabeled antibody is in a Phase 3 registration trial in patients with advanced pancreatic cancer. Immunomedics expects patient enrollment to be completed in calendar year 2016. Immunomedics' portfolio of investigational products also includes antibody-drug conjugates (ADCs) that are designed to deliver a specific payload of a chemotherapeutic directly to the tumor while reducing overall toxic effects that are usually found with conventional administration of these chemotherapeutic agents. Immunomedics' most advanced ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase 2 trials for a number of solid tumors and metastatic colorectal cancer, respectively. Immunomedics has a research collaboration with Bayer to study epratuzumab as a thorium-227-labeled antibody. Immunomedics has other ongoing collaborations in oncology with independent cancer study groups. The IntreALL Inter-European study group is conducting a large, randomized Phase 3 trial combining epratuzumab with chemotherapy in children with relapsed acute lymphoblastic leukemia at clinical sites in Australia, Europe, and Israel. Immunomedics also has a number of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various stages of clinical and preclinical development. These include bispecific antibodies targeting cancers and infectious diseases as T-cell redirecting immunotherapies, as well as bispecific antibodies for next-generation cancer and autoimmune disease therapies, created using its patented DOCK-AND-LOCK ® protein conjugation technology. The Company believes that its portfolio of intellectual property, which includes approximately 277 active patents in the United States and more than 400 foreign patents, protects its product candidates and technologies. For additional information on the Company, please visit its website at www.immunomedics.com . The information on its website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials (including the funding therefor, outcomes, timing or associated costs), out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, new product development (including clinical trials outcome and regulatory requirements/actions), the Company's dependence on business collaborations in order to further develop our products and finance our operations, the risk that we or any of our collaborators may be unable to secure regulatory approval of and market our drug candidates, risks associated with the outcome of pending litigation and competitive risks to marketed products, and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

For More Information: Dr. Chau Cheng Senior Director, Investor Relations & Corporate Secretary (973) 605-8200, extension 123

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Phoenix Contact Achieves Guinness Record in Wiring

Updated Category News Views 103

A Blitz of Wires and Innovation Boy, did Phoenix Contact shake things up in Blomberg. On a crisp November day, a group of fresh-faced first-year students pulled off something astounding—wiring 500 terminal blocks in a jaw-dropping 2 minutes and 20 seconds. This wasn’t just any effort; it was enough to earn them a shiny new Guinness World Record. What they did wasn’t...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 39

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 95

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 142

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Elite Robots Expands Global Reach with Mobile Manipulators

Updated Category News Views 10

Robots Hitting the Road? Picture this: robots that aren't just bolted to a factory floor but roam the production lines like tireless workers on wheels. That's what Elite Robots is betting on with their shiny new ELITEMISSION mobile manipulators. Not Just Any Old Robot These bad boys combine a robotic arm with an autonomous mobile platform. Think of an octopus getting off...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 423

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Stark Future Amasses €150M, Revving Up Electric Bike Dominance

Updated Category News Views 43

Well, if you've been keeping your eye on electric vehicles, this is a story that might raise those eyebrows. Stark Future, a name perhaps not buzzing on every street just yet, has gone and done it—snagged over €150 million in fresh capital. Breaking Barriers with Record-breaking Numbers Stark Future didn't just make a ripple; they caused a tsunami. This buzzing...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 52

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 53

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading

Top 5 Most Recently Viewed Articles

STMicroelectronics Unveils Latest Financial Performance Insights

Updated Category News Views 215

Overview of STMicroelectronics’ Third Quarter Results STMicroelectronics N.V. (“ST”) (NYSE: STM), a prominent figure in the semiconductor sector, announced its financial results for the third quarter, showcasing a robust revenue of $3.25 billion. This figure represents a gross margin of 37.8% and an operating margin of 11.7%, culminating in a net income of $351...

Continue Reading
Celebrating the Unique Career Opportunities at McDonald's

Updated Category News Views 654

Explore the Benefits of Working at McDonald's Finding a meaningful job can be tough, but for many, McDonald's is more than just a fast-food place. It's a stepping stone for personal and professional development. Numerous individuals have experienced major career growth thanks to their time at McDonald's, reflecting the company’s dedication to helping its employees...

Continue Reading
Key Insights on New Fortress Energy Class Action & Legal Help

Updated Category News Views 153

Understanding the New Fortress Energy Class Action Investors in New Fortress Energy Inc. (NASDAQ: NFE) should be cognizant of legal developments surrounding their investments. This class action lawsuit emerges from concerns that misrepresentations regarding the company's revenue and growth forecasts misled investors during a designated class period. Important Details...

Continue Reading
Mauna Kea Technologies Reports Promising IBS Findings with Cellvizio

Updated Category News Views 58

Mauna Kea Technologies Presents Clinical Advances for Cellvizio in IBS Mauna Kea Technologies (Euronext Growth: ALMKT), the innovative creator of Cellvizio, recently unveiled new clinical insights regarding its advanced laser endomicroscopy system. This technology showcases potential in diagnosing and managing food intolerances, specifically focusing on individuals...

Continue Reading
Resilience in Asia's Stock Markets Amid Mixed Signals

Updated Category News Views 72

Resilience in Asia's Stock Markets Amid Mixed Signals Most Asian stocks showed little movement on a recent Friday, characterized by uncertainty regarding U.S. interest rates and the approaching presidential election. However, the situation was different for Chinese shares, which turned positive following data that revealed growth in the economy, meeting investor...

Continue Reading